Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone

This publication has 26 references indexed in Scilit:

• Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers
  European Journal of Clinical Pharmacology, 2010
• Buprenorphine
  Clinical Pharmacokinetics, 2005
• Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers
  HIV Research & Clinical Practice, 2004
• Opioid substitution and HIV/AIDS treatment and prevention
  The Lancet, 2004
• Buprenorphine versus methadone maintenance: a cost-effectiveness analysis
  Drug and Alcohol Dependence, 2003
• Office-Based Treatment of Opioid-Dependent Patients
  New England Journal of Medicine, 2002
• A Liquid Chromatographic-Electrospray Ionization-Tandem Mass Spectrometric Method for Determination of Buprenorphine, Its Metabolite, norBuprenorphine, and a Coformulant, Naloxone, That Is Suitable for in Vivo and in Vitro Metabolism Studies
  Analytical Biochemistry, 2002
• Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic
  AIDS, 2002
• The Glucuronidation of Exogenous and Endogenous Compounds by Stably Expressed Rat and Human UDP-Glucuronosyltransferase 1.1
  Archives of Biochemistry and Biophysics, 1996
• THE METABOLISM AND EXCRETION OF BUPRENORPHINE IN HUMANS
  1984